Personalized Indications for CBT and Antidepressants in Treating Depression
Depression currently affects close to 2 million Canadians and is the leading cause of disability worldwide. Pharmacological treatments (antidepressant medication) and psychological treatments such as cognitive-behavioural therapy are available for depression, but the majority of those who receive treatment have an unsa
| Condition(s) | Major Depressive Disorder, Persistent Depressive Disorder |
|---|---|
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Summary | Depression currently affects close to 2 million Canadians and is the leading cause of disability worldwide. Pharmacological treatments (antidepressant medication) and psychological treatments such as cognitive-behavioural therapy are available for depression, but the majority of those who receive treatment have an unsatisfactory response. On average, the combination of pharmacological and psychological treatment achieves better results than either treatment alone. However, the apparently superior results of combination treatment may be due to the fact that different individuals preferentially respond to pharmacological or psychological treatment. The invesitagtors have discovered several clinical factors and biomarkers that predict poor response to commonly used antidepressant medication: |
| Who can participate | Inclusion Criteria: * a diagnosis of MDD or PDD established with the Structured Clinical Interview for DSM-5 (SCID-5), and depression being the primary problem requiring clinical attention (judgement of intake clinician). * a minimum current severity of 14 on the 17-item Hamilton Rating Scale for Depression (HRSD-17) * a cumulative duration of depression of at least two months (this will exclude short-lasting first depressive episodes that do not require treatment of this intensity), age 18 or more (no upper limit) * capacity to provide informed consent. Exclusion Criteria * lifetime diagnosis of bipolar disorder, schizophrenia, schizophreniform disorder, schizoaffective disorder, or current alcohol or drug use disorder * pregnancy * recent receipt of adequate trial of psychological treatm |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Nova Scotia Health Authority |
| Locations | Halifax, Nova Scotia, Canada |
| Start date | 2016-10-31 |
| NCT ID | NCT02752542 |
| Official listing | https://clinicaltrials.gov/study/NCT02752542 |